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Introduction {#rcr2538-sec-0001}
============

For decades, Liquid injectable silicone has been used for correction of contour defect or soft‐tissue augmentation. Medical‐grade liquid silicone (polydimethylsiloxane) becomes the preferred inert material for cosmetic purpose due to its durability, a lack of immunogenicity, and thermal stability; but later found to be associated with silicone embolism syndrome (SES). Liquid injectable silicone induced embolism has been reported by several studies as a cause of acute pneumonitis with alveolar haemorrhage [1](#rcr2538-bib-0001){ref-type="ref"}, [2](#rcr2538-bib-0002){ref-type="ref"}, [3](#rcr2538-bib-0003){ref-type="ref"}.

Case Report {#rcr2538-sec-0002}
===========

A previously healthy 30‐year‐old woman presented with three days history of cough with dyspnoea and fever. She had a history of breast augmentation with silicone implant two years ago and had received bilateral gluteal silicone injections from an unlicensed provider one week before the current presentation. The injected volume was approximately 500 mL for each gluteal.

The physical examination was tachycardia, tachypnoea with the respiratory rate of 28 breaths per minute and a temperature of 38°C. Results of the arterial blood gas performed while the patient was breathing room air were as follows: pH, 7.39; PaCO~2~, 40 mmHg; PaO~2~, 56 mmHg; and peripheral oxygen saturation, 90%. Lungs examination revealed bilateral lower zone crepitations. Other blood investigations which included a complete blood count, comprehensive metabolic panel, and lactate were unremarkable. She was initiated on broad‐spectrum antibiotics, oseltamivir, intravenous hydrocortisone 50 mg every 8 h, and 12 L/min (FiO2: 60%) of high‐flow oxygen supplement. However, she developed right‐sided pneumothorax and worsened respiratory failure 12 h later.

On chest radiograph, diffuse alveolar opacities in both lung fields were observed. A computed tomographic scan of her thorax demonstrated diffuse bilateral ground‐glass infiltrates (Fig. [1](#rcr2538-fig-0001){ref-type="fig"}). Fiberoptic bronchoscopy was performed, which revealed normal lung segments. Trans‐bronchial lung biopsy showed non‐refractile lipoid vacuoles, consistent with silicone pneumonitis (Fig. [2](#rcr2538-fig-0002){ref-type="fig"}). Magnetic resonance imaging of the breast confirmed no intracapsular and extracapsular rupture of the bilateral breast prosthesis. Her bronchial wash was positive for Coronavirus NL63 RNA PCR.

![A computed tomography scan of the chest (A and B) shows bilateral, diffusely distributed ground‐glass opacities with superimposed dependent areas of consolidation. Chest X‐ray (C) shows diffuse alveolar opacities of both lung fields. (D) Chest X‐ray with bilateral alveolar opacities and pneumothorax with chest tube in‐situ. (E) Chest X‐ray improvement of bilateral alveolar opacities at 6 weeks of outpatient follow‐up.](RCR2-8-e00538-g001){#rcr2538-fig-0001}

![Trans‐bronchial lung biopsy shows lung parenchyma with intra‐alveolar haemorrhage, macrophages, and non‐refractile vacuole‐like structures.](RCR2-8-e00538-g002){#rcr2538-fig-0002}

She received lung protective ventilation for acute respiratory distress syndrome (i.e. low tidal volumes and high positive end‐expiratory pressure (PEEP)) for continued hypoxia. Unfortunately, two weeks later, she again developed another spontaneous pneumothorax on the left lung and required chest tube drainage. Over four weeks in the intensive care unit, we manage to wean down the ventilatory support. She had an excellent clinical response and discharged with tapering prednisolone over two weeks. At six weeks of outpatient follow up, she was symptom‐free, and her chest X‐ray revealed residual bilateral reticulations.

Discussion {#rcr2538-sec-0003}
==========

The respiratory consequences that associated with silicone injection include acute pneumonitis [4](#rcr2538-bib-0004){ref-type="ref"}, acute respiratory distress syndrome, alveolar haemorrhages, and pulmonary embolism [5](#rcr2538-bib-0005){ref-type="ref"}. The respiratory symptoms generally present within 72 h after injection of higher dose silicone, and a delayed reaction can be seen up to a year and a half after injection [2](#rcr2538-bib-0002){ref-type="ref"}.

Pulmonary SES results from silicone embolizing to the lungs from an inadvertent intravenous injection or local tissue destruction. The neutrophils ingested the embolization of the silicone material into the lung via the haematogenous or lymphatic and alveolar macrophages induces pneumonitis by local cell‐mediated inflammation and release of free radicals and proteolytic enzymes [3](#rcr2538-bib-0003){ref-type="ref"}. The release of silicone emboli also leads to occlusion of the microvasculature and trigger the inflammatory response, resulting in pulmonary oedema and haemorrhage.

Diagnosis of the silicone pneumonitis is based on the clinical history of silicone implant or injection, the radiological pattern of subpleural infiltrates and peripherally distributed ground‐glass opacities (GGO) [6](#rcr2538-bib-0006){ref-type="ref"}, [7](#rcr2538-bib-0007){ref-type="ref"}, and tissues biopsy with histopathological features of alveolar haemorrhage [7](#rcr2538-bib-0007){ref-type="ref"} and non‐refractile vacuole‐like structure within the alveoli [1](#rcr2538-bib-0001){ref-type="ref"}. Presence of alveolar macrophages with intracytoplasmic silicone inclusions in bronchoalveolar lavage sample is useful in facilitating a diagnosis [3](#rcr2538-bib-0003){ref-type="ref"}.

Survival is likely, and treatment involves ventilation if necessary and steroids with uncertain utility. The rate of mortality is directly associated with the large volumes of silicone and high‐pressure injection [2](#rcr2538-bib-0002){ref-type="ref"}.

There is no consensus on the treatment of the silicone induced pneumonitis, but case report series show a favourable response with the use of the steroid (Table [1](#rcr2538-tbl-0001){ref-type="table"}) to reduce the airways inflammation [1](#rcr2538-bib-0001){ref-type="ref"}, [8](#rcr2538-bib-0008){ref-type="ref"}, [9](#rcr2538-bib-0009){ref-type="ref"}. General measures include nutrition and ventilation support. Extracorporeal membrane oxygenation (ECMO) may be considered in cases of severe acute respiratory distress syndrome (ARDS) deteriorating on mechanical ventilation. Surgical extraction of the silicone from subcutaneous tissues have had poor outcome due to risk of adverse systemic effects and technically complicated surgery [10](#rcr2538-bib-0010){ref-type="ref"}.

###### 

Reported cases of pulmonary silicone embolism syndrome.

  Author                                                         Year     Type of silicone application   Injection site                                       Symptoms onset after implant  Radiology findings                                                                                Complications                Treatment                                          Survival
  ---------------------------------------------------------- ------------ ------------------------------ --------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------- ---------------------------- -------------------------------------------------- ----------
  Carolyn et al. [11](#rcr2538-bib-0011){ref-type="ref"}         2019     Injection                      Gluteal                                                         2 days             Diffuse GGO                                                                                       Pneumonitis, ARDS            MTP 125 mg every six hours, ECMO                   Yes
  Ahad et al. [17](#rcr2538-bib-0017){ref-type="ref"}            2019     Implant                        Breast                                                         14 years            Alveolar infiltrates                                                                              Pneumonitis                  Corticosteroids, ECMO, antibiotics                 No
  Srilekha et al. [12](#rcr2538-bib-0012){ref-type="ref"}        2018     Injection                      ---                                                          15--20 years          Diffuse GGO                                                                                       Pneumonitis, pneumothorax    Corticosteroids                                    No
  Elizabeth et al. [13](#rcr2538-bib-0013){ref-type="ref"}       2018     Implant                        Breast                                                         16 years            Hilar & mediastinal LN, pulmonary nodules                                                         Pulmonary nodules            Prednisone 40 mg/day tapering down over 6 months   Yes
  Implant                                                       Breast    2 years                        Diffuse micro‐nodules with GGO                               Pneumonitis           Implant removal, prednisone 40 mg/day                                                             Yes                                                                             
  Implant                                                       Breast    12 years                       Diffuse GGO and reticular opacities                      Organising pneumonia      Prednisone 40 mg/day with tapering down over 6 months and azathioprine as steroid sparing agent   Yes                                                                             
  Arthur et al. [18](#rcr2538-bib-0018){ref-type="ref"}          2018     Implant                        Breast                                                         6 months            Alveolar infiltrates, diffuse GGO                                                                 Pneumonitis, PH              Implant removal, prednisolone 40 mg/day, ECMO      Yes
  Rafael et al. [19](#rcr2538-bib-0019){ref-type="ref"}          2017     Implant                        Gluteal                                                        4 months            ---                                                                                               Granulomatous inguinal LN    Capsulotomy                                        Yes
  María et al. [20](#rcr2538-bib-0020){ref-type="ref"}           2016     Implant                        Breast                                                         10 years            Consolidation                                                                                     Pneumonitis                  Implant removal, corticosteroids                   Yes
  Kirill et al. [21](#rcr2538-bib-0021){ref-type="ref"}          2016     Injection                      Gluteal                                                        2 months            Diffuse GGO                                                                                       Pneumonitis                  Supportive                                         Yes
                                                                          Injection                      Gluteal                                                        8 months            Diffuse GGO, mediastinal & hilar LN                                                               Pneumonitis                  Supportive                                         Yes
  Ayush et al. [22](#rcr2538-bib-0022){ref-type="ref"}           2016     Implant                        Breast                                                         18 years            Diffuse GGO                                                                                       Pneumonitis                  Implant removal, corticosteroids                   Yes
  Erin et al. [23](#rcr2538-bib-0023){ref-type="ref"}            2015     Injection                      Gluteal                                                        5 months            Alveolar infiltrates                                                                              Gluteal abscess, ARDS        Incision and drainage, antibiotics                 Yes
  Alex et al. [24](#rcr2538-bib-0024){ref-type="ref"}            2013     Injection                      Gluteal                                                         2 days             Diffuse GGO                                                                                       Pneumonitis, PH              MTP 125 mg every six hours                         Yes
  Dercio et al. [25](#rcr2538-bib-0025){ref-type="ref"}          2012     Injection                      Gluteal                                                         2 week             Alveolar infiltrates                                                                              Pneumonitis                  Corticosteroids                                    Yes
  Denyo et al. [26](#rcr2538-bib-0026){ref-type="ref"}           2012     Injection                                                                                     36--48 h            Alveolar infiltrates                                                                              Pneumonitis, PH              ---                                                ‐
  Injection                                                               36--48 h                       Alveolar infiltrates                                       Pneumonitis, PH         ---                                                                                               ‐                                                                               
  Priya et al. [27](#rcr2538-bib-0027){ref-type="ref"}           2011     Injection                      Gluteal                                                          6 h               Diffuse GGO                                                                                       Pneumonitis, PH              Supportive                                         Yes
  Sophie et al. [28](#rcr2538-bib-0028){ref-type="ref"}          2010     Injection                      Gluteal, hip                                                    1 day              Noncalcified pulmonary nodules, GGO                                                               Pneumonitis                  MTP                                                Yes
  Rupen et al. [29](#rcr2538-bib-0029){ref-type="ref"}           2008     Injection                      Thigh                                                           3 days             Alveolar infiltrates                                                                              Pneumonitis                  MTP                                                Yes
  Richard et al. [30](#rcr2538-bib-0030){ref-type="ref"}         2008     Injection                      Gluteal, thigh, face                                             4 h               Alveolar infiltrates                                                                              Organising pneumonia, ARDS   MTP                                                No
  Rafael et al. [31](#rcr2538-bib-0031){ref-type="ref"}          2007     Injection                      Breast                                                           40 h              Alveolar infiltrates                                                                              Pneumonitis, ARDS            Supportive                                         No
  Grigoriy et al. [32](#rcr2538-bib-0032){ref-type="ref"}        2006     Injection                      Gluteal                                                        12 days             Alveolar infiltrates                                                                              Pneumonitis, PH              MTP 250 mg every six hours                         Yes
  Samuel et al. [33](#rcr2538-bib-0033){ref-type="ref"}          2006     Injection                      Gluteal                                                          ---               Subpleural GGO and consolidation                                                                  Pneumonitis, PH              Supportive                                         ‐
  Alex et al. [34](#rcr2538-bib-0034){ref-type="ref"}            2004     Injection                      Breast                                                          1 week             Alveolar infiltrates                                                                              Pneumonitis, PH              Corticosteroids                                    Yes
  Cheol et al. [35](#rcr2538-bib-0035){ref-type="ref"}           2003     Injection                      Vaginal colpoplasty                                             2 days             Interstitial infiltrates, air‐space consolidation                                                 Pneumonitis                  Corticosteroids                                    Yes
  Jean et al. [3](#rcr2538-bib-0003){ref-type="ref"}             1983     Injection                      Trochanter                                                      3 days             ---                                                                                               Pneumonitis                  Supportive                                         Yes
  Injection                                                   Trochanter  2 days                         ---                                                          Pneumonitis           Supportive                                                                                        Yes                                                                             
  Injection                                                   Trochanter  1 day                          Interstitial infiltrates, air‐space consolidation            Pneumonitis           Supportive                                                                                        Yes                                                                             

ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; GGO, ground glass opacities; LN, lymphadenopathy; MTP, methylprednisolone; PH, pulmonary haemorrhages.

Carolyn et al. reported a case of acute pneumonitis after silicone injection for gluteal augmentation. The patients presented with haemoptysis, shortness of breath, and acute respiratory failure two days after the silicone injections [11](#rcr2538-bib-0011){ref-type="ref"}. Her computed tomography (CT) thorax showed predominantly basilar and peripheral GGO and pulmonary nodules bilaterally. She required ECMO and her condition improved with intravenous methylprednisolone 125 mg every 6 h.

Srilekha Sridhara et al. reported a rare case of silicone pneumonitis with pneumothorax occurred even after 15--20 years of silicone injection [12](#rcr2538-bib-0012){ref-type="ref"}. Bronchoscopic lung biopsy demonstrated alveolar interstitium with numerous lipoid vacuoles, compatible with silicone deposition. The patient succumbed despite treated with intravenous corticosteroids, broad‐spectrum antibiotics, and mechanical ventilation.

Elizabeth et al. reported three cases of breast implants with the onset of symptoms ranges 2--16 years [13](#rcr2538-bib-0013){ref-type="ref"}. The CT features of these patients demonstrated diffuse GGO. All three patients responded to prednisolone 40 mg/day.

Our case demonstrates the features of SES after the gluteal silicone filler. No specific site for vascular infiltration was identified in our case; however, many injection marks were observed on the buttocks. MRI breast confirmed that there is no leak from the silicone breast implants and no residual collection in the gluteal region. Thus, the decision not to remove the breast implant and not for surgical exploration of the possibilities of remaining gluteal silicone collection was made after a multidisciplinary meeting comprises of pulmonologist, plastic and reconstructive surgeon, and anaesthetic team. A trans‐bronchial lung biopsy was deemed to be a less invasive approach to obtain lung biopsies in order to avoid the risk of general anaesthesia due to poor pulmonary reserve.

The detection of HCoV‐NL63 in our patient is incidental. This is consistent with the literature that HCoV‐NL63 can be frequently found in asymptomatic individuals [14](#rcr2538-bib-0014){ref-type="ref"}. Although, HCoV‐NL63 can infects both the upper and lower respiratory tract, it generally associated with mild symptoms, such as fever, cough, pharyngitis, and rhinitis [15](#rcr2538-bib-0015){ref-type="ref"}. In rare cases, pneumonia can occur. In total contrast to silicon pneumonitis, lung biopsy histopathological features of HCoV‐NL63 pneumonia are chronic pulmonary inflammation, severe alveolar damage, intra‐alveolar hyaline membranes, and interstitial oedema [16](#rcr2538-bib-0016){ref-type="ref"}. The result of the lung biopsy of our patient was consistent with the diagnosis of silicone pneumonitis.

Learning points for our case includes:Corticosteroids are potentially beneficial in reduces the inflammation of the airways that leading pneumonitis with acute respiratory distress syndrome but does not have any mortality benefits [3](#rcr2538-bib-0003){ref-type="ref"}, [14](#rcr2538-bib-0014){ref-type="ref"}.Lung‐protective ventilation strategies improve survival.Vigilance in the occurrence of pneumothorax in cases of SES especially if complicated with ARDS and requiring mechanical ventilation. Risk of pneumothorax in SES and will usually resolve after chest drain intervention.Trans‐bronchial lung biopsy is useful in assisting the diagnosis.Patients should be advised that there is a risk that silicone injections can be associated with serious pulmonary complications.

The injection of silicone for cosmetic purpose is debatable due to the sequelae of the pneumonitis and the potential for pulmonary toxicity in asymptomatic patients who receive silicone injections. Bronchoalveolar lavage and trans‐bronchial lung biopsy can help to confirm the diagnosis. This case report serves to highlight an emergent danger associated with illicit silicone use for cosmetic purposes and clinicians should be aware of the potential complications.

Disclosure statement {#rcr2538-sec-0004}
--------------------

Appropriate written informed consent was obtained for publication of this case report and accompanying images.
